Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis Almost 5 Years After First Approval
Analysis of almost 5 years of real-world use of esketamine in the United States remains consistent with the established safety profile from clinical studies and current product labeling. No new safety signals were identified.
Authors
- Oliver Lopena
- Brianne Brown (ORCID: https://orcid.org/0000-0002-5856-6344)
- Patricia Cabrera (ORCID: https://orcid.org/0000-0002-8696-4278)
- Hannah E. Bowrey (ORCID: https://orcid.org/0000-0002-3774-4201)
- David M. Kern (ORCID: https://orcid.org/0000-0001-5417-3925)
- Amir Sarayani (ORCID: https://orcid.org/0000-0003-2790-9938)
- Mai Himedan
- Gerard Sanacora (ORCID: https://orcid.org/0000-0003-3722-8829)
- Ibrahim Turkoz (ORCID: https://orcid.org/0000-0003-1891-2297)
- Isaac Nuamah
- Teodora Doherty
- Ronaldo R. Naranjo
- Muhammad Ahmed (ORCID: https://orcid.org/0000-0003-3803-5359)
- Lisa Lim
Institutions
- The University of Sydney (AU)
- Johnson & Johnson (United States) (US)
- Yale University (US)
- Johnson & Johnson (Australia) (AU)
Publication Details
- Journal
- American Journal of Psychiatry
- Published
- 2025-09-10
- DOI
- https://doi.org/10.1176/appi.ajp.20240655
- Citations
- 13
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 18.13